The American Academy of Orthopaedic Surgeons launched a new online pain management resource center for orthopedic surgeons and patients, according to a press release.
“Very few of the organizations in the country have taken a lead on trying to figure out how to reduce opioids in orthopedics — and medicine, for that matter,” Vinod Dasa, MD, FAAOS, cochair of AAOS’s National Initiative to Reduce Opioid Use in Orthopaedics , told Healio. “There is a lot of interest and a lot of demand from patients, policy makers and insurance companies that we make improvements in

Women in midlife with vasomotor symptoms who initiated menopausal hormone therapy, or MHT, during perimenopause or shortly after menopause had a 22% lower risk for CVD, new data show.
Prior literature in this area is mixed, with studies capturing both beneficial and adverse impacts of MHT on cardiovascular health, according to Ziyuan Wang, PhD, an advisor pharmacoepidemiology at Eli Lilly and Company, and colleagues.
“The FDA’s move to remove the broad black box warnings from MHT products underscores the need for updated evidence to guide safety assessments,” they wrote in JAMA Internal

Care for acute retinal ischemia, an event comparable to a stroke in the eye, could be accelerated through immediate nonmydriatic fundus photography and OCT, according to a study.
“Similar to the brain, the retina has a very short tolerance to ischemia and a time-dependent ‘penumbra’ beyond which irreversible injury occurs,” Madhuri Akella, MD, of the department of ophthalmology at Emory University School of Medicine, and colleagues wrote in Frontiers in Neurology. “Recent studies have shown that the implementation of nonmydriatic fundus photography and optical

Approximately 40% of men with prostate cancer treated with concurrent androgen deprivation therapy and androgen receptor pathway inhibitors may develop metabolic syndrome within a year.
A retrospective analysis of nearly 17,000 patients showed the first metabolic condition, usually hypertension, occurs within the first month.
“Patients who receive ARPI and ADT have immense benefits to overall survival. However, monitoring for metabolic abnormality needs to happen early and systematically in treatment,” Amy L. Shaver, PhD, PharmD, MPH, principal biostatistician at Thomas Jefferson University,

Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA has granted investigational device exemption to Ciliatech’s Intercil uveal spacer for glaucoma, according to a company press release.
With the approval, the company plans to begin a new feasibility study to evaluate the safety and performance of the device in approximately 30 patients with primary open-angle glaucoma, according to the release.
Intercil in a hydrophilic acrylic implant designed to support uveoscleral outflow by creating supraciliary spacing. The company said it is meant to be a

Editor’s Note: This is part two of a three-part Healio Dermatology back-to-school skin series, where experts discuss common adolescent skin conditions, treatments and trends. Read part one here .
An essential part of back-to-school shopping for many young girls now includes a trip to a high-end makeup store for pricey skin care products marketed to adults, a social media-inspired trend dermatologists are watching with caution.
“It seems to start somewhere around 8 or 9 years old and interest becomes broader around the end of middle school,” Heather D. Rogers, MD, FAAD, a dermatologist in

Once-weekly injectable Wegovy plus lifestyle modification conferred a greater reduction in BMI than placebo among children aged 6 to 11 years with obesity, according to topline results from the STEP Young trial.
The STEP Young trial assessed the efficacy and safety of semaglutide (Wegovy, Novo Nordisk) among 165 children with obesity. Participants were randomly assigned to semaglutide or placebo for 68 weeks in conjunction with a reduced-calorie diet and physical activity. More than 85% of the trial participants had class 2 or class 3 obesity. Children receiving semaglutide were given a

With “Undetectable = Untransmittable,” or U = U, the message is clear: People with HIV who maintain an undetectable viral load on treatment cannot sexually transmit the virus to people without HIV.
The longstanding U = U awareness campaign, which spotlights the effectiveness of modern HIV medications, has roots that go back a decade.
This message, however, is more nuanced when it comes to breastfeeding with HIV.
In an editorial published in The Lancet HIV, Dvora Joseph Davey, PhD, an infectious diseases epidemiologist and associate professor at UCLA, and colleagues addressed the

The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a), failed to achieve its primary outcome, Novartis announced.
There are no therapies currently approved to lower Lp(a), high levels of which occur in about one in five people and are associated with elevated risk for CV events. Lp(a) levels are mostly genetically determined and generally do not change based on lifestyle. Pelacarsen (Novartis/Ionis), an antisense oligonucleotide, is the first of many Lp(a)-lowering agents in development to have results from a phase 3 CV

Pinhole pupilloplasty is a modality to create a pinhole pupil of desired size and location in reference to the vertex of the cornea.
Studies have documented the optimization of pinhole size and its customization according to the patient’s response to a pinhole device placed in front of the patient’s eye with varying diameters ranging from 0.5 mm to 4 mm (gradually increasing in 0.5 mm increments). The pinhole size that allows the best visual acuity is chosen, and an attempt is made intraoperatively to replicate the same.
 
However, we recently documented decentration of the pinhole pupil in